Nursing Elites

1. A patient has been taking hydrocodone, an opioid analgesic for their moderate pain, and they have taken more than the prescribed dose. What should you administer as the antidote if they experience toxicity?

• A. Naloxone
• B. N-acetylcysteine
• C. Atropine
• D. Digoxin immune Fab

Correct answer: A

Rationale: Naloxone is the specific antidote for opioid toxicity. It works by blocking the effects of opioids on the central nervous system, thereby reversing symptoms like respiratory depression and sedation. N-acetylcysteine is used for acetaminophen overdose, while atropine is indicated for certain types of poisonings. Digoxin immune Fab is used for digoxin toxicity. Therefore, in the case of opioid toxicity due to hydrocodone overdose, naloxone is the appropriate antidote.

2. What is the classification of Ondansetron?

• A. Antihypertensive
• B. Antiarrhythmic
• C. Antiemetic
• D. Antiulcer agent

Correct answer: C

Rationale: Ondansetron is classified as an antiemetic. It is commonly used to prevent nausea and vomiting, especially in patients undergoing chemotherapy or surgery. Choice A, Antihypertensive, is incorrect as Ondansetron is not used to treat high blood pressure. Choice B, Antiarrhythmic, is incorrect as Ondansetron is not used to manage heart rhythm abnormalities. Choice D, Antiulcer agent, is incorrect as Ondansetron is not primarily indicated for treating ulcers.

3. A client has a new prescription for Raltegravir. Which of the following statements should the nurse include in teaching the client?

• A. This medication prevents the virus from entering the cell.
• B. This medication prevents the virus from leaving the cell.
• C. This medication blocks the virus from attaching to the cell.
• D. This medication blocks the virus from replicating in the cell.

Correct answer: D

Rationale: The correct answer is D because Raltegravir works by blocking the integrase enzyme, preventing the virus from integrating its genetic material into the host cell's DNA. By inhibiting this process, viral replication within the host cell is halted. Choices A, B, and C are incorrect because Raltegravir's mechanism of action specifically targets viral replication within the cell, not virus entry, exit, or attachment to the cell.

4. A client is receiving treatment with bevacizumab. Which of the following findings should the nurse monitor?

• A. Hypertension
• B. Hypokalemia
• C. Hyperglycemia
• D. Hypocalcemia

Correct answer: A

Rationale: Corrected Rationale: Bevacizumab is known to potentially cause hypertension as a common adverse effect. The nurse should monitor the client's blood pressure regularly to detect and manage any elevations effectively. Choices B, C, and D are incorrect because bevacizumab is not typically associated with causing hypokalemia, hyperglycemia, or hypocalcemia. Therefore, monitoring for hypertension is the priority in this case.

5. Which drug undergoes extensive first-pass hepatic metabolism?

• A. Heparin
• B. Insulin
• C. Propranolol
• D. Nitroglycerin

Correct answer: C

Rationale: Propranolol undergoes extensive first-pass hepatic metabolism in the liver. When administered orally, propranolol is extensively metabolized by the liver before reaching systemic circulation, leading to reduced bioavailability. This process is known as first-pass hepatic metabolism, which significantly affects the drug's effectiveness and necessitates higher oral doses compared to other routes of administration. Heparin (Choice A) is not metabolized by the liver but excreted unchanged by the kidneys. Insulin (Choice B) is a peptide hormone that is not subject to significant first-pass metabolism. Nitroglycerin (Choice D) is primarily metabolized in the blood and tissues, bypassing significant first-pass metabolism in the liver.

Similar Questions